Brought to you by 
Clovis gets rights to Clavis's gemcitabine conjugate; terminated
10 Dec 2015
Executive Summary
Swedish cancer company Clavis Pharma ASA has granted Clovis Oncology (formed earlier this year by former Pharmion execs to develop new therapeutics) rights to develop, manufacture, and sell its pancreatic cancer candidate CP4126 in the US, Europe, Canada, and Central and South America.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis gets rights to Clavis's gemcitabine conjugate; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice